(±) -Equol (Standard)

(±) -Equol (Standard) is the analytical standard of (±) -Equol. This product is intended for research and analytical applications. (±) -Equol is the racemate of equol. (±) -equol exhibits EC50s of 200 and 74 nM for human ERα and ERβ, respectively. Equol is a metabolite of the soy isoflavones, daidzin and daidzein.

Product Specifications

CAS Number

[94105-90-5]

UNSPSC

12352005

Target

Drug Metabolite; Estrogen Receptor/ERR; Reference Standards

Related Pathways

Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Neurological Disease; Cardiovascular Disease

Smiles

OC1=CC=C2CC(C3=CC=C(O)C=C3)COC2=C1

Molecular Formula

C15H14O3

Molecular Weight

242.27

References & Citations

[1]Axelson M, et al. The identification of the weak oestrogen equol [7-hydroxy-3- (4'-hydroxyphenyl) chroman] in human urine. Biochem J. 1982 Feb 1;201 (2) :353-7.|[2]Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81 (5) :1072-9. human intestinal bacterial flora.|[3]Wang J, et al. Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor. Genet Mol Res. 2014 Jul 4;13 (3) :5055-63.|[4]Gimenez I, et al. Renal and vascular actions of equol in the rat. J Hypertens. 1997 Nov;15 (11) :1303-8.|[5]Choi EJ, et al. Anticancer mechanism of equol in 7,12-dimethylbenz (a) anthracene-treated animals. Int J Oncol. 2011 Sep;39 (3) :747-54.|[6]Charoenthongtrakul S, et al. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther. 2009;329 (3) :1178-1186.